A novel phase 1 trial explores the safety and efficacy of targeted radiotherapy for leptomeningeal metastases in breast cancer patients.
Andrew Brenner, MD, PhD
Advertisement
Andrew Brenner, MD, PhD, is a breast and neuro-oncology specialist and professor of medicine in the Division of Hematology and Oncology at the University of Texas Health Science Center at San Antonio.
Articles by Andrew Brenner, MD, PhD
Phase 1 data presented by Andrew Brenner, MD, PhD, showed RNL-186 improved survival, reduced symptoms, and demonstrated strong safety in patients with leptomeningeal metastases.
Advertisement
Latest Updated Articles
LM Reduction Seen in Phase 1 Trial for Breast Cancer: Andrew Brenner, MD, PhDPublished: December 17th 2025 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
CDC Reduces US Childhood Immunization Schedule From 17 to 11 Diseases
2
GLP-1s More Effective at Preventing Colorectal Cancer Than Aspirin
3
Telemedicine Utilization and Preventive Services Among a Rural Population
4
Nimbus Therapeutics, Eli Lilly Partner to Develop Novel Oral Metabolic Drug
5
